LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Advanced Lab-on-Chip Optical Biosensors Offer Fast, Efficient Point-of-Care COVID-19 Testing

By LabMedica International staff writers
Posted on 09 Sep 2021
Print article
Image: A sample optical detection platform for rapid COVID-19 diagnosis (Photo courtesy of Asghari et al.)
Image: A sample optical detection platform for rapid COVID-19 diagnosis (Photo courtesy of Asghari et al.)
Advanced lab-on-a-chip optical biosensors can enable fast accurate point of care COVID-19 diagnosis, according to researchers.

Researchers from the University of Texas at Austin (Austin, TX, USA) and Omega Optics Inc. (Austin, TX, USA) investigated the opportunities and challenges in developing rapid COVID-19 sensing techniques. Without the prospect of herd immunity on the immediate horizon, speedy detection for COVID-19 remains imperative for helping to curb the pandemic. Point-of-care testing that can provide immediate results is an urgent need.

One of the most promising solutions to accurate rapid testing is using optical biosensors. When a virion is present on the surface of an optical sensor, its interaction with a light beam on the sensor affects the light's properties, causing a measurable shift in the light signal. Even with only a very small viral dosage, the system can reliably detect the coronavirus in real time. There are a number of different ways in which this interaction can be utilized and improved upon, such as integrating it with measurements of plasma oscillations or incorporating graphene into its fabrication process.

Each potential configuration uses a different mechanism to sense the virus and has its own set of advantages and drawbacks, but the primary takeaway remains the same. Even with the widespread availability of vaccines, the pandemic cannot be overcome without developing faster ways to determine infection, particularly as mutations and new variants of the virus continue to arise.

"Due to growing cases resulting from more transmissible variants around the world and the need to prevent and control cases and outbreaks when they arise, we should be utilizing rapid testing more commonly to detect and stop the spread before hitting the transmission peak," said Aref Asghari, one of the researchers. "In case of COVID-19, the viral load at the onset of infection can be low enough to not be detected by many commercially available methods. Therefore, viral detection, especially at earlier infection stage, can be very challenging."

Related Links:
University of Texas at Austin
Omega Optics Inc.


Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.